Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Budget Addresses Medicare Fraud, Beefs Up Data Infrastructure

This article was originally published in The Gray Sheet

Executive Summary

While President Obama's fiscal 2011 budget request does not seek the broad coverage expansions and Medicare reforms pursued by languishing comprehensive health care reform bills, it attempts to make progress around the edges with attention to fighting Medicare fraud and beefing up CMS

You may also be interested in...



Payment Reform Demands Faster Demo Project Timetable, Policy Experts Say

The slow pace of designing and implementing Medicare demonstration projects is hindering efforts at much-needed payment reform, according to speakers at the AcademyHealth National Health Policy Conference Feb. 8-9 in Washington, D.C

Payment Reform Demands Faster Demo Project Timetable, Policy Experts Say

The slow pace of designing and implementing Medicare demonstration projects is hindering efforts at much-needed payment reform, according to speakers at the AcademyHealth National Health Policy Conference Feb. 8-9 in Washington, D.C

AtriCure settlement

Firm enters "tentative" agreement with the Department of Justice Nov. 4 to settle allegations of illegal off-label promotion of its Isolator cardiac ablation devices for atrial fibrillation treatment. AtriCure proposes to pay $3.8 million, plus interest, over five years and enter into a corporate integrity agreement with the HHS Office of Inspector General. However, AtriCure admits no wrongdoing. The firm's Isolator bipolar ablation system and Coolrail linear ablation device are FDA-cleared for ablating cardiac tissue during surgical procedures, but not specifically for AF. Johnson & Johnson/Biosense Webster's NaviStar ThermoCool catheters remain the only FDA-approved AF ablation catheters on the market. AtriCure was among five companies facing whistleblower lawsuits for off-label promotion of ablation catheters. Medtronic, Boston Scientific and St. Jude Medical are still under investigation, while Endoscopic Technologies settled related allegations in July for $1.4 million (1"The Gray Sheet" July 20, 2009)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028460

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel